X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Canadian And US Developers To Test Psychedelic Drugs In UK

Content Team by Content Team
14th December 2022
in Clinical Trials, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

To take advantage of the UK’s quick medication approval procedures, the North American psychedelic drug companies Mindset, PharmAla, Mydecine, and Psyence have inked a contract with the clinical research organisation (CRO) Clerkenwell Health to test treatments for mental health disorders there.

Autism Spectrum Disorder (ASD), social anxiety, nicotine addiction, adjustment disorder in patients with terminal cancer, and major depressive disorder (MDD),  are among the mental health disorders that the companies seek to treat.

Companies can expedite their ethics submissions and combine their reviews thanks to the regulatory pathway and quick drug approval process in the UK. Since the UK’s trial data is widely acknowledged, many businesses conduct their Phase I and Phase II trials there before entering bigger markets like the US. Since the joint review process was implemented in 2018, approval durations have decreased by half, and in August 2022, fast-track ethical applications that enable approvals in 60 days were introduced.

Developers of psychedelic drugs from North America and Canada who will test their treatments in the UK

A psilocybin-based medication is being developed by Denver, Colorado-based Mydecine to treat adult tobacco addiction. They gave this substance to John Hopkins University, which used it in a study to help Americans quit smoking. This was the first time in 50 years that a study examining a psychedelic molecule for therapeutic purposes was funded by the US government.

PharmAla, a Toronto-based company that is the sole producer of clinical-grade MDMA in North America, has created a pharmacological molecule based on 3,4-Methylenedioxy Methamphetamine (MDMA) to cure social anxiety in adults with ASD. Through the trial approval procedure for both the British and US regulators, Clerkenwell Health will assist the company. The US Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) are the respective regulators.

A psilocybin-like substance for treating MDD is among the medicines being developed by Toronto-based Mindset. With plans to begin conducting the experiment in 2023, Clerkenwell Health, which recently launched Europe’s first commercial facility devoted to psychedelic-assisted therapy, is aiding Mindset with regulatory submissions and scientific guidance.

The MHRA has given Toronto-based biotech company Psyence permission to conduct clinical trials of its psilocybin-assisted therapy for patients with terminal cancer. Psyence is a facility in South Africa where it grows psilocybin mushrooms, which it sends to Portugal and Canada for study.

They are thrilled to pursue their research on how second-generation psychedelic drugs to treat neurological and psychiatric diseases could assist many patients in the UK, said James Lanthier, CEO of Mindset.

According to Jessica Riggleman, Senior Director of Clinical and Regulatory Affairs at Mydecine Innovations Group, drug developers now have the option to seek priority review using the Innovative License and Access Pathway, in which the time to market is reduced for a wide range of medicines under development.

Previous Post

Future Biotech Platforms Likely To Depend Primarily On Urine

Next Post

New Zealand Health Agencies Aim To Improve Clinical Trials

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

New Zealand Health Agencies Aim To Improve Clinical Trials

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In